The current gold standard for aneurysm treatment is endovascular coiling. However, recurrence is 16 observed in over 20% of cases. A novel hydrogel has been developed to treat aneurysms. This hydrogel 17 is composed of a polymeric alginate, a novel ion releasing glass and glucono-delta-lactone. This is an 18 internally setting alginate hydrogel, wherein the setting rate can be controlled by both the glass and the 19 alginate chemistry. The aim of this work is to examine the effect of each component of the hydrogel and 20 optimise the composition of the hydrogel, specifically the alginate molecular weight, M/G ratio and 21 concentration. The effects of gamma sterilisation will also be examined. The results show that alginate 22 concentration, chemical composition and molecular weight affect the compressive strength, working time, 23 hardening time and deliverability of the hydrogel. Gamma irradiation of the alginate reduces the 24 molecular weight, which has a negative effect on the usability of this hydrogel. 25 26
Introduction 30
An intracranial aneurysm is an irregular out-pouching of a cerebral artery. It is estimated that 1% to 6% of 31 the adult population has an intracranial aneurysm (Brisman, Song, & Newell, 2006) . A ruptured aneurysm 32 can lead to stroke, resulting in disability or death. Treatments such as clipping and coiling are currently 33 used to prevent an aneurysm from rupturing; however, there are a number of problems associated with 34 these. Clipping the aneurysm involves a craniotomy and carries the risks of infection and scarring 35 (Brisman et al., 2006) . In the United States, the most common treatment method for intracranial 36 aneurysms is coiling. However, recurrence is common, happening in 20.8% of endovascular coiling cases 37 (Crobeddu, Lanzino, Kallmes, & Cloft, 2012), indicating that it is a suboptimal treatment method. 38
In this study we explore the possibility of delivering a hydrogel which will fill the aneurysm more 39 completely and prevent rupture. This novel hydrogel composite is composed of a polymeric alginate, a 40 novel ion releasing glass and glucono-delta-lactone (GDL). 41
Ideally, the hydrogel should adhere to the aneurysm wall preventing migration and aneurysm recurrence. 42
Additionally, the hydrogel must be able to withstand a compressive stress of at least 22kPa, which relates 43 to hypertensive blood pressure (Cipolla MJ, 2009). The envisaged hydrogel delivery procedure will 44 involve inflating a compliant balloon adjacent to the aneurysm neck, as with endovascular coiling. The 45 novel hydrogel will then be injected through a micro-catheter into the aneurysm whilst the inflated 46 balloon prevents leakage of the filler into the blood stream (see Figure S 1 ). To allow for delivery, an 47 optimum working time of between 10 and 30 minutes has been determined by clinical observation. It has 48 been determined that the novel hydrogel must be set within 5 minutes of injection (based on the 49 maximum inflation time for a balloon in the cerebral vasculature. A balloon inflated for greater than 5 50 minutes may result in cerebral ischemia (Kim Nelson & Levy, 2001) . The alginate sterility must also be 51 considered and this can ordinarily be achieved by moist heat sterilization, gamma-irradiation or ethylene 52 oxide sterilization (Munarin, Bozzini, Visai, Tanzi, & Petrini, 2013) . 53
Alginate is a polysaccharide composed of β-ᴅ-mannuronic acid (M) and α-ι-guluronic acid (G), giving 54 alginate an M/G block structure. Alginate has the ability to gel when cross-linked with multivalent ions. 55
Alginate is typically described in terms of molecular weight and the M/G ratio. G-rich alginates are 56 stiffer and more brittle than M-rich alginates (Morais et al., 2013) . 57
The role of the glass in this hydrogel is to deliver a steady release of multivalent ions, controlling the rate 58 of gelation and the strength of the hydrogel. The more stable the glass the slower the rate of gelation. A 59 glass that releases a higher quantity of ions will form a stronger hydrogel. Bioactive glasses have also 60 traditionally been used to deliver therapeutic ions, which encourage cell growth and extracellular matrix 61 production. This hydrogel formulation could also, in the future, be used to deliver therapeutic ion doses.
GDL is a lactone that hydrolyses in water to form a gluconic acid, its role in the novel hydrogel is to 63 acidify the solution. This in turn releases multivalent ions, contained in the glass, allowing them to cross-64 link with the alginate. The gelation rate of the hydrogel can be tightly controlled by both the composition 65 of the glass phase and the ratio of constituent components of the gel. An increased amount of GDL results 66 in increased acidity, causing a more rapid glass ion release and a more rapid gelation. 67
The aim of this work is to individually vary the concentration of two different alginates, with similar 68 viscosities but differing molecular weights and M/G ratios and to examine the effect on the mechanical 69 properties, sample volume conservation, working time, hardening time and deliverability of a hydrogel. 70
We hypothesise that the strength of the hydrogel will increase with increasing alginate concentration but 71 the sample size will reduce over time due to the increased cross-linking density. Although alginate is a 72
Non-Newtonian liquid that undergoes shear thinning, there will likely be a large increase in viscosity with 73 increasing alginate concentration and this will affect the deliverability of the hydrogel. In addition, the 74 effect of a reduction in molecular weight by sterilisation on the most suitable alginate is subsequently 75 examined. Gamma irradiation is known to greatly reduce the molecular weight of alginate and will likely 76 cause a significant reduction in the hydrogel's strength. This will also reduce the viscosity which may 77 help with the deliverability of the hydrogel. Gamma irradiation will be chosen as a possible sterilisation 78 technique for future work, provided there is a positive outcome of these results. This optimisation is 79 designed to improve the novel hydrogel's performance for the treatment of cerebral aneurysms. 80 All reagents used were purchased from Sigma-Aldrich (Wicklow, Ireland), unless stated otherwise. Two 86 different techniques were used to produce the two different potassium alginates; a medium viscosity high-87 G content alginate (MVG) and a medium viscosity high-M content alginate (MVM). The hydrogel was 88 purified from a sodium salt and alginate to a potassium alginate to reduce the endotoxin levels found in 89 the supplied alginate (Dusseault et al., 2006) . All acid/base solutions were made up in 20 mmol/L of NaCl 90 in deionised water (DI), unless stated otherwise. 91 MVG was produced by dissolving 8g of a sodium salt from brown algae in 400 mL of DI. The alginate 92 pH was raised to 7.0 by adding a 0.5 M potassium hydroxide (KOH). The alginate was then precipitated 93 by adding 200 mL of methanol per 100 mL of alginate. The alginate was filtered through a 500 µm sieve 94 after 10 minutes. The alginate was then freeze-dried. 95 MVM was produced by dissolving 9 g of sodium alginate was dissolved in 900 mL of 1 mmol/L sodium 96 EGTA. The solution was then filtered through 11 µm and 2.5 µm filter paper respectively. The alginate 97 was then precipitated on ice by reducing the pH to 1.5 using a 2 M hydrochloric acid (HCl). The alginate 98 was decanted through a 500 µm stainless sieve and stirred 30 minutes in 200 mL of a 0.01 M HCl 99 solution and decanted again. This stirring and decanting was repeated three times. To remove proteins the 100 alginate was stirred for 30 minutes in 100 mL of a 0.01 M HCl solution with 20 mL of chloroform and 5 101 mL of 1-butanol, and collected in a 500 µm stainless steel sieve. This washing and collecting was 102 repeated three times. 350 mL of DI was added and the pH was raised to 7.0 by adding a 0.5 M KOH. The 103 alginate was stirred in a solution of 20 mL chloroform and 5 mL of 1-butanol per 100 mL of alginate and 104 centrifuged at a rate of 5,000 rpm for 5 minutes. The alginate was then separated using a pipette from the 105 chloroform/1-butanol solution. This washing and centrifuging was repeated once. Finally, the alginate 106 was precipitated by adding 200 mL of ethanol per 100 mL of alginate and filtered after 10 minutes. The 107 alginate was then freeze-dried. 108
Material and Methods
A sample of the porous freeze-dried solid MVM alginate was gamma irradiated at Synergy Healthcare 109 (Westport, Ireland) by exposing the sample to a cobalt 60 source until a final irradiation dose of 25kGy 110 was achieved. 111
The required amount of freeze-dried alginate, to make the required alginate concentration, was then added 112 to 12 mL of DI. 113
Glass 114
The glass had a mole fraction composition of 0.33SiO2•0.18Ga2O3•0.23CaO•0.11P2O5•0.15CaCl2. A glass 115 frit of this composition was produced by melting the appropriate raw materials in a platinum 10% 116 rhodium crucible at 1480 °C for 1 hour. The molten mixture was then shock quenched into water. A glass 117 powder was then produced by grinding 30 g of glass frit using 15 mm diameter zirconia balls in a ball 118 mill (Pulverisette 6 classic Mono planetary ball mill, Fritsch GmbH, Germany) at 500 rpm for 10 119 minutes. Particles over 500 µm were removed by sieving the glass powder through a 500 µm sieve. 7.5 g 120 of the <500 µm particles were ground in 22.5 mL of DI using 5 mm zirconia balls in a ball mill at 500 121 rpm for 10 minutes. The glass mixture was dried in the oven at 130 ºC. 122
Glucono-Delta-Lactone 123
D-(+)-Gluconic acid δ-lactone was purchased from Sigma Aldrich. The GDL particle size was reduced by 124 grinding 30 g at 500 rpm for 5 minutes using a ball mill. Particle size analysis is shown in Figure S 
Hydrogel preparation 126
The required amount of freeze-dried alginate was dissolved in 1.2 mL of DI. The novel hydrogel was 127 produced by mixing 4.6% of glass powder, 50 mg of GDL with the 1.2 mL of the alginate solution for 1 minute, unless otherwise stated. Design Expert 9 (Stat-Ease, Minneapolis, USA) was used to determine 129 the four alginate concentrations to be tested; 0.5%, 2.5%, 4.5% and 6.0%. 130 131  132 2.2.1. Alginate Characterisation 133
Methods
Gel permeation chromatography (GPC) and nuclear magnetic resonance spectroscopy ( 1 H NMR) were 134 carried out as follows in order to characterise the alginates produced. 135 GPC was carried out using a liquid chromatography system (Agilent 1200, Agilent, USA) equipped with 136 a Suprema Linear GPC column (PSS, Germany). The mobile phase used consisted of 0.1 M disodium 137 hydrogen phosphate containing 0.5 g/L of sodium nitrate buffered to pH 9. All samples were injected at a 138 concentration of 1 mg/mL, at a flow rate of 0.5 mL/min. Pullulan standards were used to construct the 139 calibration curves as alginate standards are not available. This is not an ideal standard as it can 140 was used to bring the alginate pH to 5.6 and the alginate solution was stored in a water bath at 100 °C for 147 1 hour. HCl was used to further adjust the pH of the alginate to 3.8. The solution was stored again in a 148 water bath at 100°C for 30 minutes. The pH was then raised to 7 using NaOH and the alginate was freeze 149 dried. The alginate was then dissolved in 5 mL of 99% D2O and freeze dried overnight. 12 mg of alginate 150 was dissolved in 1 mL of D2O and placed in a NMR tube. The NMR of the alginate was tested using a 151 Bruker Advance 400 (Bruker, Massachusetts, USA) at 80°C. 64 scans were carried out using a 2s 152 relaxation delay. The M-block, G-block and alternating block sequences content were then calculated as 153 per the equations in ASTM F2259-03 using the produced spectrum. 154 155
Viscosity 156
The viscosity of each alginate at varying concentrations was determined at 24ºC using a SV-10 tuning 157 forks Vibro Viscometer (A&D Company, Japan) running a sine wave formation at a constant frequency 158 of 30Hz and amplitude of less than 1 mm. The viscometer measures up to 10,000 mPa.s. 159
Volume Conservation 160
To examine whether the 1.2 mL hydrogel volume was conserved over time, the samples volumes were 161 measured after storage in 20 mL of DI for 1, 3 and 7 days. The hydrogel was mixed and poured into a cylindrical mould (10 mm diameter and 14 mm height). The hydrogel was left to set for 1 hour and 163 incubated in DI at 37°C for the required amount of time. After the required time the hydrogel was 164 removed from the DI and dimensions were measured using callipers. 'Volume conservation' was 165 calculated by calculating the change in volume compared to the original (pre-incubated) volume. 166
Compression testing 167
To examine the mechanical properties of the novel hydrogel, compression testing was carried after storing 168 the novel hydrogel for 7 days in DI. The compression testing samples were made as described above. 169
After the required amount of time the hydrogel sample was compressed using a mechanical testing 170 machine (Z005, Zwick Roell, Germany) equipped with a 5 kN load cell. A 0.005 N pre-load was applied. 171
The samples were compressed up to 70% strain at a crosshead speed of 2 mm/min. 172
Working and Hardening Time 173
The working and setting time of each alginate was determined using a modified version of ISO 9917. The 174 setting time was found by mixing the hydrogel and placing a circular indenter (diameter: 6 mm, weight: 175 20 g) on the sample every 60 seconds. The hydrogel was considered set when it held the indenter without 176 causing an indentation in the hydrogel. 177
The working time was determined by stirring the hydrogel every 1 minute until the hydrogel would not 178 return to its original shape. 179
The hardening time is defined as the difference between the setting time and working time of the 180 hydrogel. 181
Deliverability 182
The deliverability of each alginate was tested by injecting the hydrogel by hand at the varying alginate 183 concentrations through a 3F micro catheter, using a quick stop syringe. 184
The optimum hydrogel was then injected through a 2.7F micro-catheter into a silicone side wall 185 aneurysm, (neck size of 2.5 x 6 mm, model H+N-S-A-005, Elastrat, Switzerland). A pulsatile blood pump 186 (1423, Harvard Apparatus, Mass., USA) was used to pump a 36:64 water:glycerol solution through the 187 aneurysm and to provide physiologically correct blood pressure (140/80 mmHg) and flow rates (700 mL 188 l/min). The pressure was measured at the aneurysm inlet and outlet using pressure transducers (DTX Plus 189 Disposable Pressure Transducer, Argon) which was amplified using a bridge analogue input (NI9237, 190 National Instrument) and the pressure was monitored using LabView. A 5 mm diameter balloon (Trek, 191 Abbott) was inflated adjacent to the aneurysm neck, to facilitate placement. 192
Statistical analysis 193
Student GPC was carried out to determine the molecular weight (MW) of each alginate and 1 H NMR spectra of 201 the alginates were used to determine the guluronic acid (FG), mannuronic acid (FM) and alternating block 202 (FGM) fractions, which were calculated as per ASTM F2259 -03. 203 Table 1 gives the calculated results of the alginates produced; see Figure S The volume of the samples with a low alginate concentration reduced in size, see Figure 1 . A 4.5% 210 alginate concentration approximately maintains its size or slightly expands (<5%) whilst the samples at 211 the 6.0% alginate concentration expanded after 7 days. 212 observed here. The decreased strength observed at 4.5% and 6.0% may be caused by shortage of cross-228 linking cations. As there is no increase in GDL or glass content there will be no increase in ion 229 availability to cross-link with increasing number of chains provided by the increased alginate 230 concentration. 231 Figure 3 shows that increasing the glass content increases the modulus and strength of the hydrogel at a 232 4.5% alginate concentration. Increasing the glass content from 4.6% to 9.2% more than doubles both the 233 strength and modulus of the hydrogel, with no further increase being observed with further glass addition 234 (13.8%). This may be increased further with an increase in GDL content. The alginate concentration of 0.5% (either MVG or MVM) gave insufficient viscosity (41-44mPas) to 249 remain in the aneurysm when blood flow was applied. The 2.5% and 4.5% alginate concentration of both 250 MVG and MVM alginates (<10,000 mPa.s) would inject through the micro-catheter easily, up to 20 251 minutes after mixing. The MVG and MVM alginates at 6.0% alginate concentration (>10,000 mPa.s) 252 would not inject through the micro-catheter, blocking it 2 minutes after mixing the hydrogel. 253
As the 4.5% concentration of the MVM alginate had the correct strength, sufficient volume conservation, 254 and correct working and hardening times it was selected to inject into the aneurysm model. With the 255 balloon inflated and the flow pump on, the hydrogel was injected into the 10 mm aneurysm with a 256 2.5x2.5 mm neck two minutes before the end of the working time (22 minutes after mixing). The 257 hydrogel was fully injected by the working time and the balloon remained inflated for two minutes. The 258 hydrogel stayed within the aneurysm and remained in the aneurysm with no perceptible erosion once the 259 balloon was deflated for the time tested (30 minutes). 260
Effect of Gamma Irradiation 261
As previously stated, the MVM alginate was the more suitable of the two alginates examined for 262 treatment of cerebral aneurysms and hence was selected for gamma irradiation. A sample of the alginate was gamma irradiated by Synergy Healthcare (Westport, Ireland) at 25kGy to examine the effects of a 264 change in molecular weight alone and for sterilisation purposes. 265
Alginate Characterisation 266
GPC and 1 H NMR showed that gamma irradiation causes a reduction in alginate molecular weight to 267 180kDa without a change to the alginate chemical composition (Table 1) . 268 Figure 5 shows that, again, the lower irradiated alginate concentrations shrink in volume whilst the 6.0% 270 alginate concentration increases in volume over 7 days for both alginates. 
Volume Conservation 269

Compression testing 280
Reduction in molecular weight caused by gamma irradiation greatly affects the compressive stress and 281 incremental modulus of the hydrogel compared to the non-irradiated sample (p > 0.05). Although the 282 gamma irradiated alginate has a compressive strength that exceeds the limit discussed in the introduction 283 (22 kPa), the incremental modulus of the alginate decreases with increasing alginate concentration and at 284 each concentration has a decreased strength compared to the non-irradiated alginate, see Figure 6 . 
Deliverability 298
None of the gamma irradiated alginate concentrations had sufficient viscosity to remain in the aneurysm 299 when blood flow was applied, similar to that of the 0.5% alginate concentration of the non-irradiated 300 alginate. 301
Discussion 302
From the GPC and 1 H NMR results we can see that two different alginates were produced, a MVM with a 303 high molecular weight and a MVG with a low molecular weight. Though the molecular weight of the MVG alginate is over ten times less than that of the MVM alginate, the viscosities are similar ( Figure S The sample volume conservation exhibits results similar to those described by Kuo et al (Catherine K 318 Kuo & Ma, 2008) . At a 0.5% and 2.5% alginate concentration the samples shrink and the 4.5% and 6.0% 319 alginate concentration samples expand (Figure 1 ). This may be due to the hydrogel's cross-linking 320 density decreasing with increasing alginate concentration as a result of the glass content, and hence ion 321 content, remaining constant. The lower concentration alginates have an increased cross-linking density. 322
This increased cross-linking increases the elastic forces that can resist the swelling caused by water 323 molecules diffusing into the hydrogel. As the concentration increases the cross-linking density decreases 324 allowing water to diffuse through the hydrogel and swell. Neither significant shrinkage nor expansion is 325 desired, as shrinkage may contribute to aneurysm recurrence and excessive sample expansion may cause 326 aneurysm rupture. Samples produced from 4.5% alginate concentration exhibit minimal swelling, which 327 suggests that this alginate concentration provides a cross-linking density that provides a high strength 328
while conserving sample volume. 329
For both the MVG and MVM alginate the incremental modulus and compressive strength increase from 330 0.5% to 2.5% alginate concentration (Figure 2) . The incremental modulus and compressive strength then 331 decreases with further increased alginate concentration (≥2.5%). The decrease above 2.5% alginate was 332 unexpected and may be due to a shortage of cross-linking ions. This shortage of ions may reduce the 333 cross-linking density and result in an inhomogeneous hydrogel that is prone to fracture. To explore this 334 further, the glass content was increased. This increased the strength for the 4.5% and 6.0% alginate 335 concentration whereby the increase in cations provided a higher cross-linking density (Figure 3 the gamma irradiated alginate may be improved by increasing alginate concentration and optimising the 363 glass and GDL content, an alternative method of sterilization may be more efficient, such as sterilisation 364 by filtration in a sterile manufacturing environment. 365 A range of injectable polymer formulations have been developed for soft tissue applications but many 366 contain toxic monomers, activators and free radicals. The gelation rate of the hydrogel described here is 367 slow compared to other alginate hydrogels (Larsen, Bjørnstad, Pettersen, Tønnesen, & Melvik, 2015; Lee 368 et al., 2003) , which allows the hydrogel to be delivered and set, within a clinically applicable time. 369
Though GDL can be used with alginate to produce acid gels, this is likely not the case with the current 370 hydrogel due to the high strengths and relatively rapid gelation rates observed. The addition of GDL 371 results in a reduced pH during setting, which may affect the hydrogel's biocompatibility. The pH of the 372 storage medium drops by 0.50 with the 4.5% high-M alginate. However, the presence of alkali ions in the 373 bioactive glass has a neutralizing effect over 24 hours. It should be noted that this temporary reduction in 374 pH, as occurs with many synthetic biomaterials, may result in an increased inflammatory and fibrotic Agglomerates were clearly visible in the hydrogel both during and after setting, which may affect 394 consistency of strength and setting, therefore, future testing will be carried out to minimise these 395 agglomerates. The adhesive nature of the hydrogel will also be examined as this is important to reduce 396 aneurysm recurrence. Further optimisation of the sterilisation techniques for each hydrogel component of 397 the hydrogel will also need prior to commercial application. 398
Conclusion
From the results it can be seen that alginate concentration, molecular weight and chemical composition 400 affect the sample volume conservation, viscosity, strength, deliverability, working and hardening time of 401 the novel hydrogels. An alginate with an increased molecular weight and high-M content provides a 402 hydrogel with an increased working time and decreased hardening time while providing the required 403 strength which is advantageous for a cerebral aneurysm filler. Alginates with a viscosity between 2,000 404 mPa.s and 9,000 mPa.s can be injected through a micro catheter while providing sufficient viscosity to 405 remain within an aneurysm without migration. 406
Sterilisation by gamma irradiation causes a reduction of molecular weight which decreases the alginate's 407 viscosity and strength and increases the hydrogel's working and hardening time. This is undesirable for 408 the treatment of cerebral aneurysms. For this application, an alternative, less aggressive method of 409 sterilisation will be required. 410 
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